Harvard Bioscience
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Harvard Bioscience generated cash of $14,028,000, which is more than the previous year. Cash used in financing activities reached the amount of -$12,134,000 last year. Net change in cash is therefore -$225,000.
Cash Flow
| 2014 | 4.35M | -13.51M | -1.23M |
|---|---|---|---|
| 2015 | 705K | -7.51M | -540K |
| 2016 | 5.38M | -62K | -4.86M |
| 2017 | 1.05M | -917K | -1.79M |
| 2018 | 2.34M | -53.25M | 53.05M |
| 2019 | 8.04M | -229K | -7.62M |
| 2020 | 9.33M | -1.40M | -7.96M |
| 2021 | 1.26M | -1.34M | -252K |
| 2022 | 1.15M | -1.59M | -2.83M |
| 2023 | 14.02M | -1.79M | -12.13M |
HBIO Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 4.50M | 7.82M | 8.31M | 8.33M | 8.17M | 5.73M | 5.59M | 6.74M | 14.13M | 25.77M |
Operating activities | ||||||||||
Net income | -3.41M | -9.51M | -288K | -7.81M | -4.68M | -3.46M | -865K | -4.30M | -19.03M | 2.35M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 6.99M | 7.57M | 7.62M | 7.63M | 7.73M | 7.88M | 3.80M | 4.27M | 4.57M | 3.87M |
Stock-based compensation expense | 5M | 4.41M | 4.16M | 3.64M | 3.03M | 0 | 3.5M | 3.49M | 2.75M | 2.15M |
| Deferred income tax benefit | 5M | 4.41M | 4.16M | 3.64M | 3.03M | 0 | 3.5M | 3.49M | 2.75M | 2.15M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 810K | 4.78M | -4.29M | 3.10M | 468K | -2.79M | 196K | 566K | -1.34M | -735K |
Inventories | 1.52M | 252K | -5.86M | 413K | 3.26M | 2.55M | -548K | 1.24M | -1.22M | -3.05M |
Accounts payable | 555K | -1.39M | -540K | 511K | -2.04M | 1.59M | -918K | -2.41M | 2.57M | 1.06M |
Cash generated by operating activities | 14.02M | 1.15M | 1.26M | 9.33M | 8.04M | 2.34M | 1.05M | 5.38M | 705K | 4.35M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.78M | -1.59M | -1.34M | -1.15M | -1.21M | -986K | -890K | -1.47M | -2.97M | -2.00M |
Acquisitions Net | 512K | 0 | 0 | 0 | 1.00M | -52.25M | 12K | 1.41M | -4.54M | -12.65M |
Cash generated by investing activities | -1.79M | -1.59M | -1.34M | -1.40M | -229K | -53.25M | -917K | -62K | -7.51M | -13.51M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 577K | 3.31M | 0 | 0 | 4.55M | 0 | 182K | 2.04M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -1.62M | -3.51M | -1.14M | -221K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -10.54M | -1.78M | -52K | -68.80M | -7.40M | -20.19M | -1.95M | -9.05M | -2.55M | -5.5M |
Cash used in financing activities | -12.13M | -2.83M | -252K | -7.96M | -7.62M | 53.05M | -1.79M | -4.86M | -540K | -1.23M |
Net Change In Cash | -225K | -3.31M | -496K | -18K | 162K | 2.44M | 137K | -1.14M | -7.39M | -11.63M |
Cash at end of period | 4.28M | 4.50M | 7.82M | 8.31M | 8.33M | 8.17M | 5.73M | 5.59M | 6.74M | 14.13M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |